18 August 2016 - First intravenous anti-IL-5 biologic therapy for severe eosinophilic asthma now approved in Europe.

Teva Pharmaceuticals  today announced that the European Commission has granted marketing authorization for Cinqaero (reslizumab) in the 28 countries of the European Union in addition to Norway, Liechtenstein and Iceland.

Cinqaero is a humanized interleukin-5 antagonist monoclonal antibody for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Read Teva Pharmaceuticals press release